Ardelyx (ARDX) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Geron (GERN) has outperformed Ardelyx (ARDX) over the past year, losing 11.6% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -13.5% for GERN. Ardelyx is the larger company by market cap ($846.9 million vs $787.0 million), about 1.1 times the size.
On valuation, Ardelyx trades at a lower forward P/E (11.3x vs 30.6x for Geron).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | GERN |
|---|---|---|
| Share price | $3.28 | $1.23 |
| Market cap | $846.86M | $787.03M |
| 1-day change | +0.31% | +0.41% |
| YTD return | -43.91% | -7.58% |
| 1-year return | -35.38% | -11.59% |
| 5-year return | +202.78% | -13.48% |
| Forward P/E | 11.29 | 30.63 |
| EPS (TTM) | $-0.23 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $2.01 |
| 52-week low | $3.18 | $1.04 |
| Distance from 52-week high | -60.95% | -39.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +293.29% | +246.94% |
| Average volume | 4.17M | 10.07M |
| Shares outstanding | 258.19M | 642.47M |
| Employees | 489 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GERN has outperformed ARDX by 23.8 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
ARDX vs GERN FAQ
Which is bigger, Ardelyx or Geron?
Ardelyx (ARDX) is larger, with a market capitalization of $846.86M compared with $787.03M for Geron (GERN).
Which stock has performed better over the past year, ARDX or GERN?
GERN returned -11.59% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.